Canada | Imports and Exports | World | Pharmaceutical products | Value (US$) and Value Growth, YoY (%) | 2012 - 2023
The value of exports of commodity group 30 "Pharmaceutical products" from Canada totalled $ 9.58 billion in 2023. Sales of commodity group 30 from Canada decreased by 10.6% in value terms compared to 2022. exports of commodity group 30 "Pharmaceutical products" decreased by $ 1.13 billion (cumulative exports of commodity group 30 from Canada amounted $10.7 billion in 2022)
Exports of commodity group 30 "Pharmaceutical products" amounted to 1.69% of total exports from Canada (cumulative merchandise exports from Canada totalled $ 566 billion in 2023). The share of commodity group 30 in total exports from Canada decreased by 0.106 p.p. compared to 2022 (it was 1.79% in 2022 and cumulative exports from Canada were equal to $ 596 billion).
Where does Canada export Pharmaceutical products?
Top export destinations of "Pharmaceutical products" from Canada in 2023:
- USA with a share of 70% (6.74 billion US$)
- Japan with a share of 7.38% (708 million US$)
- Italy with a share of 3.17% (304 million US$)
- Belgium with a share of 2.21% (212 million US$)
- China with a share of 2.03% (195 million US$)
- Netherlands with a share of 1.9% (182 million US$)
- France with a share of 1.44% (138 million US$)
- United Kingdom - 86 million US$
- Ireland - 82 million US$
- Australia - 70 million US$
Exports structure of 30 - Pharmaceutical products - from Canada in 2023 represented by the following main commodity groups:
- 86% (8.26 billion US$): 3004 - Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale
- 8.92% (855 million US$): 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc
- 2.66% (255 million US$): 3006 - Pharmaceutical goods specified in Note 4 to this Chapter.
- 1.43% (137 million US$): 3003 - Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale
- 0.368% (35 million US$): 3005 - Wadding, gauze, bandages and similar articles (for example, dressings, adhesive plasters, poultices), impregnated or coated with pharmaceutical substances or put up in forms or packings for retail sale for medical, surgical, dental or veterinary purposes.
- 0.356% (34 million US$): 3001 - Glands, organs (extracts, secretions thereof) for organo-therapeutic uses, dried, powdered or not; heparin and its salts; other human or animal substances for therapeutic or prophylactic uses n.e.s.
The value of imports of commodity group 30 "Pharmaceutical products" to Canada totalled $ 18.8 billion in 2023. Sales of commodity group 30 to Canada decreased by 5.79% in value terms compared to 2022. imports of commodity group 30 "Pharmaceutical products" decreased by $ 1.16 billion (the value of imports of commodity group 30 to Canada was equal to $20 billion in 2022)
Imports of commodity group 30 "Pharmaceutical products" accounted for 3.38% of total import flow to Canada (in 2023, total imports to Canada amounted to $ 558 billion). The share of commodity group 30 in total imports to Canada decreased by 0.137 p.p. compared to 2022 (it was 3.52% in 2022 and cumulative imports to Canada were equal to $ 569 billion).
Where does Canada import Pharmaceutical products from?
Top trading partners (import of "Pharmaceutical products") of Canada in 2023:
- USA with a share of 27% (5.16 billion US$)
- Germany with a share of 11.4% (2.15 billion US$)
- Portugal with a share of 10% (1.89 billion US$)
- Switzerland with a share of 8.23% (1.55 billion US$)
- Ireland with a share of 7.16% (1.35 billion US$)
- Denmark with a share of 5.87% (1.11 billion US$)
- Belgium with a share of 5.16% (976 million US$)
- Sweden with a share of 2.88% (544 million US$)
- France with a share of 2.82% (533 million US$)
- India with a share of 2.81% (531 million US$)
Imports structure of 30 - Pharmaceutical products - to Canada in 2023 represented by the following main commodity groups:
- 50% (9.49 billion US$): 3004 - Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale
- 35% (6.63 billion US$): 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc
- 10.4% (1.98 billion US$): 3003 - Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale
- 2.19% (414 million US$): 3006 - Pharmaceutical goods specified in Note 4 to this Chapter.
- 1.32% (250 million US$): 3005 - Wadding, gauze, bandages and similar articles (for example, dressings, adhesive plasters, poultices), impregnated or coated with pharmaceutical substances or put up in forms or packings for retail sale for medical, surgical, dental or veterinary purposes.
- 0.562% (106 million US$): 3001 - Glands, organs (extracts, secretions thereof) for organo-therapeutic uses, dried, powdered or not; heparin and its salts; other human or animal substances for therapeutic or prophylactic uses n.e.s.
